Citigroup
ORKA

Citigroup’s Oruka Therapeutics ORKA Stock Holding History

Citigroup’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.39M Buy
67,101
+56,714
+546% +$3.78M ﹤0.01% 1938
2026
Q1 		$509K Buy
10,387
+559
+6% +$19.4K ﹤0.01% 3529
2025
Q4 		$298K Buy
9,828
+6,457
+192% +$180K ﹤0.01% 3819
2025
Q3 		$64.8K Sell
3,371
-6,469
-66% -$95.9K ﹤0.01% 4410
2025
Q2 		$110K Buy
9,840
+8,286
+533% +$86.4K ﹤0.01% 4356
2025
Q1 		$15.9K Sell
1,554
-6,474
-81% -$80.7K ﹤0.01% 5125
2024
Q4 		$156K Sell
8,028
-18,692
-70% -$456K ﹤0.01% 4575
2024
Q3 		$655K Buy
+26,720
New +$930K ﹤0.01% 3558
2022
Q2 		– Sell
-149
Closed -$4K – 6743
2022
Q1 		$4K Buy
+149
New +$3.69K ﹤0.01% 5918
2016
Q2 		– Hold
0
– – – 7486
2016
Q1 		– Sell
-1
Closed -$814 – 7808
2015
Q4 		$1K Buy
+1
New +$1.13K ﹤0.01% 7428
2015
Q3 		– Hold
0
– – – 7761
2015
Q1 		– Sell
-1
Closed -$1K – 7475
2014
Q4 		$1K Buy
+1
New +$1.51K ﹤0.01% 7003
2014
Q3 		– Sell
-2
Closed -$4K – 7336
2014
Q2 		$4K Buy
+2
New +$4.65K ﹤0.01% 6558
2013
Q3 		– Sell
-3
Closed -$6K – 7024
2013
Q2 		$6K Buy
+3
New +$9.16K ﹤0.01% 6280

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citigroup's ORKA Position: Q2 2026 in Review

Citigroup increased its Oruka Therapeutics (ORKA) stake by 546% in Q2 2026, buying an estimated $3.78M and bringing the position to 67,101 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Citigroup first reported a position in ORKA in Q2 2013 and has held it in 13 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Citigroup held 67,101 shares of Oruka Therapeutics worth $6.39M as of Q2 2026.
  • Citigroup bought 56,714 Oruka Therapeutics shares in Q2 2026, an estimated $3.78M.
  • Oruka Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1938 holding.
  • Citigroup first reported a position in Oruka Therapeutics in Q2 2013 and has held it in 13 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.